Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Dropped 22.6% in First Half of 2022

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 105.4 million yuan in the first half of 2022, down 22.6% year-on-year.

Meanwhile, the company posted 4.6 billion yuan in revenue, down 1.3% year-on-year.

At the end of the reporting period, it had 7.1 billion yuan in total assets and 4.7 billion yuan in total liabilities, with a liability-to-asset ratio of 67.3%.